Susquehanna Fundamental Investments’s Nurix Therapeutics NRIX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-117,282	Closed	-$1.34M	–	704
2025 Q2	$1.34M	Sell	117,282 -28,192	-19%	-$305K	0.04%	406
2025 Q1	$1.73M	Buy	+145,474	New	+$2.43M	0.02%	556
2022 Q1	$459K	Buy	32,769 +2,688	+9%	+$47.7K	0.01%	1110
2021 Q4	$871K	Sell	30,081 -1,361	-4%	-$41.3K	0.02%	703
2021 Q3	$942K	Buy	+31,442	New	+$970K	0.02%	892
2021 Q1	–	Sell	-8,300	Closed	-$273K	–	1593
2020 Q4	$273K	Sell	8,300 -700	-8%	-$23.2K	0.01%	1281
2020 Q3	$314K	Buy	+9,000	New	+$227K	0.01%	1049

Other funds holding NRIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna Fundamental Investments's NRIX Position: Q3 2025 in Review

Susquehanna Fundamental Investments sold out of Nurix Therapeutics (NRIX) in Q3 2025, closing a stake of 117,282 shares — an estimated $1.34M sold.

Susquehanna Fundamental Investments first reported a position in NRIX in Q3 2020 and held it in 7 quarters. The position peaked at $1.73M in Q1 2025. 173 funds tracked by Wall St. Rank hold NRIX as of Q3 2025.

Susquehanna Fundamental Investments reported no remaining Nurix Therapeutics position as of Q3 2025 after selling out during the quarter.
Susquehanna Fundamental Investments sold 117,282 Nurix Therapeutics shares in Q3 2025, an estimated $1.34M.
Susquehanna Fundamental Investments first reported a position in Nurix Therapeutics in Q3 2020 and held it in 7 quarters.
Susquehanna Fundamental Investments's Nurix Therapeutics position peaked at $1.73M in Q1 2025.
173 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2025, filed 14 Nov 2025.